TITLE

SINOVAC GETS SFDA APPROVAL TO BEGIN EV71 VACCINE TRIALS

PUB. DATE
February 2011
SOURCE
Worldwide Biotech;Feb2011, Vol. 23 Issue 2, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an approval received by Sinovac Biotech Ltd. from the China State Food and Drug Administration (SFDA) to begin clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). Majority of HFMD cases happen in children under five years old. According to Sinovac Chairman, President and Chief Executive Officer (CEO) Weidong Yin, the company aims to contribute to the prevention and control of the disease.
ACCESSION #
57671637

 

Related Articles

  • SINOVAC BIOTECH SUBMITS CLINICAL TRIAL APPLICATION FOR PCV.  // Worldwide Biotech;Apr2011, Vol. 23 Issue 4, p4 

    The article reports the clinical trial application of biopharmaceutical firm Sinovac Biotech Ltd. for its 13-valent pneumococcal conjugate vaccine (PCV) to the State Food and Drug Administration (SFDA) of China. The vaccine regulatory system of the SFDA passed the evaluation of the World Health...

  • Clinic Roundup.  // BioWorld Today;12/29/2010, Vol. 21 Issue 250, p5 

    The article reports that the China State Food and Drug Administration has approved an application by Sinovac Biotech Ltd. to commence clinical trials for its inactivated EV71 vaccine against hand, foot and mouth disease.

  • Clinic Roundup.  // BioWorld Today;1/11/2012, Vol. 23 Issue 7, p6 

    This section offers news briefs on clinical trials. A Phase II trial of poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor was relaunched by Cancer Research UK. The U.S. Food and Drug Administration has granted its approval to an investigational new drug application from Immuron...

  • Sinovac: Panflu on track in pandemic flu.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p38 

    The article reports on the completion of Sinovac Biotech Ltd.'s phase I clinical trial of its avian influenza vaccine Panflu on the shot regimen of either the vaccine or placebo. The action represents another step on the product candidate's way to becoming a much-needed addition to global...

  • Sinovac Jumps on Results for Hand, Foot and Mouth Vaccine. Shaffer, Catherine // BioWorld International;3/20/2013, Vol. 18 Issue 12, p4 

    The article discusses the results of the Phase III double-blind, randomized, placebo-controlled study for enterovirus (EV71) vaccine to prevent hand, foot, and mouth disease (HFMD). The study was conducted between children who are 6 months and 5 years old in Jiangsu, China from January to March...

  • Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore.  // Biomedical Market Newsletter;6/19/2011, p382 

    The article reports on the initiation of the phase 1 clinical trial of INV21, a hand, foot and mouth disease (HFMD) investigational vaccine from Inviragen Inc. in Singapore. It states that the study will be conducted at the National University Health System under the company's memorandum of...

  • Sinovac Jumps on Results for Hand, Foot and Mouth Vaccine. Shaffer, Catherine // BioWorld Today;3/15/2013, Vol. 24 Issue 50, p1 

    The article discusses the results of the Phase III data of the double-blind, randomized, placebo-controlled trial of Sinovac Biotech Ltd.'s enterovirus 7I (EV 7I) vaccine which reveal efficacy, immunogenicity and safety against hand, foot and mouth disease (HFMD). The data showed a 95.4 percent...

  • Research Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug...

  • VACCINE REPORT.  // BioPharm International;Feb2008, Vol. 21 Issue 2, p12 

    The article offers news briefs related to vaccine developments. Apitope Technology Ltd. launched ATX-MS-1467, a therapeutic vaccine, which is safe for secondary progressive multiple sclerosis (SPMS) patients. Sinovac Biotech Ltd. conducted a positive clinical trial of pandemic influenza (H5N1)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics